Elevated Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Elevated Capital Advisors's BMY Position: Q2 2026 in Review
Elevated Capital Advisors reduced its Bristol-Myers Squibb (BMY) stake by 25% in Q2 2026, selling an estimated $110K and leaving 5,669 shares worth $327K. The position accounts for 0.09% of the portfolio, ranked #193.
Elevated Capital Advisors first reported a position in BMY in Q4 2025 and has held it in 3 quarters since. The position peaked at $460K in Q1 2026. 2,526 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Elevated Capital Advisors held 5,669 shares of Bristol-Myers Squibb worth $327K as of Q2 2026.
- Elevated Capital Advisors sold 1,923 Bristol-Myers Squibb shares in Q2 2026, an estimated $110K.
- Bristol-Myers Squibb made up 0.09% of Elevated Capital Advisors's portfolio in Q2 2026, its #193 holding.
- Elevated Capital Advisors first reported a position in Bristol-Myers Squibb in Q4 2025 and has held it in 3 quarters since.
- Elevated Capital Advisors's Bristol-Myers Squibb position peaked at $460K in Q1 2026.
- 2,526 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Elevated Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.